Medical Digest & Congress Report

Professor Jalid Sehouli explains how to break the wall of platinum-resistance in ovarian cancer at the ESMO Congress 2025.

Video: https://medicaldigest.org/scientific-contents/interview:how-proc-breaking-wall-platinum-resistance-ovarian-cancer

Professor Thomas B. Powles discuss the results from IMvigor011, a phase 3 trial of ctDNA-guided adjuvant atezolizumab versus placebo in muscle invasive bladder cancer were presented at the ESMO Congress 2025.

Video: https://medicaldigest.org/scientific-contents/interview:imvigor011-phase-3-trial-ctdna-guided-adjuvant-atezolizumab-versus-placebo-mibc

Professor Sibylle Loibl shares her thoughts on the additional analyses of DESTINY-Breast09 were presented at the ESMO Congress 2025. Key subgroup analysis of DESTINY-Breast09 confirms efficacy of trastuzumab deruxtecan plus pertuzumab for treating HER2+ advanced or metastatic breast cancer across groups.

Video: https://medicaldigest.org/scientific-contents/interview:t-dxd-effective-treating-her2-advanced-or-metastatic-breast-cancer-regardless-treatment-history-hr-status-or-pik3c-mutations

Professor Emanuela Romano explains what's new in ESMO guidelines on hepatocellular carcinoma, cutaneous melanoma, Hodgkin Lymphomas and early stage and locally advanced non-small cell lung cancers at the ESMO Congress 2025.

Video: https://medicaldigest.org/scientific-contents/interview:whats-new-esmo-guidelines

Professor Jeanne Tie shares her thoughts on the DYNAMIC-III trial results were presented at the ESMO Congress 2025.

Video: https://medicaldigest.org/scientific-contents/interview:dynamic-iii-trial-results-ctdna-blood-test-powerful-tool-guide-treatment-choices-people-advanced-colon-cancer

Professor Dirk Schadendorf shares his thoughts on the overcoming therapeutic challenges in high-risk cutaneous squamous cell carcinoma at the ESMO Congress 2025.

Video: https://medicaldigest.org/scientific-contents/interview:overcoming-therapeutic-challenges-high-risk-cutaneous-squamous-cell-carcinoma-multidisciplinary-approach

Professor Christof Vulsteke shares her thoughts on the data from the phase 3 KEYNOTE-905 trial were presented at the ESMO Congress 2025. A treatment regimen consisting of neoadjuvant enfortumab vedotin-ejfv plus pembrolizumab, radical cystectomy plus pelvic lymph node dissection, and adjuvant EV plus pembrolizumab yielded significant improvements in multiple outcomes in patients with muscle-invasive bladder cancer who are ineligible for or decline cisplatin-based chemotherapy.

Video: https://medicaldigest.org/scientific-contents/interview:keynote-905-paves-way-next-generation-mibc-trials

Professor Maria De Santis shares her thoughts on the final analysis of the phase 3, open-Label, randomized POTOMAC trial were presented at the ESMO Congress 2025.

Video: https://medicaldigest.org/scientific-contents/interview:durvalumab-combination-bcg-bcg-naive-high-risk-nmibc-final-analysis-phase-3-open-label-randomized-potomac-trial

Professor Hisham M. Mehanna shares his thoughts on the treatment landscape in resectable LA HNSCC at ESMO 2005 at the ESMO Congress 2025.

Video: https://medicaldigest.org/scientific-contents/interview:treatment-landscape-resectable-la-hnscc

Professor Danny Rischin shares his thoughts on the analysis of second primary cutaneous squamous cell carcinoma tumors reported during the C-POST trial were presented at the ESMO Congress 2025. The study is a randomized phase III study of adjuvant cemiplimab vs placebo for high-risk CSCC.

Video: https://medicaldigest.org/scientific-contents/interview:analysis-second-primary-cutaneous-squamous-cell-carcinoma-tumors-reported-during-c-post-trial